FDA reversing course on adcomm should reassure Travere investors, says BofA

After Travere Therapeutics (TVTX) announced that the FDA informed the company it no longer plans to hold an advisory committee meeting to review the sNDA for Filspari for focal segmental glomerulosclerosis, BofA analyst Jason Zemansky notes that shares are up pre-market and says the news should reassure investors about approval. With the FDA’s update arguably strengthening the outlook for approval by the PDUFA date of January 13, the firm sees potential for the “next leg of growth for Filspari,” says the analyst, who maintains a Buy rating and $29 price target on Travere shares.